Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001856:Bone Marrow Examination; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D004357:Drug Synergism; D005260:Female; D006689:Hodgkin Disease / Q000145:classification / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage* / Q000009:adverse effects; D012075:Remission, Spontaneous; D012737:Sex Factors; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects
D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone